OBJECTIVE: To report the 3-year toxicity and outcomes of carbon 11 (11C)-choline-positron emission tomography (PET)/computed tomography (CT)-guided radiotherapy (RT), delivered via helical tomotherapy (HTT; Tomotherapy® Hi-Art II® Treatment System, Accuray Inc., Sunnyvale, CA, USA) after lymph node (LN) relapses in patients with prostate cancer. PATIENTS AND METHODS: From January 2005 to March 2013, 81 patients with biochemical recurrence after surgery, with or without adjuvant/salvage RT or radical RT, and with evidence of LN 11C-choline-PET/CT pathological uptake, underwent HTT (median [range] prostate-specific antigen level 2.59 [0.61-187] ng/mL). Of the 81 patients, 72 were treated at the pelvic and/or lumbar-aortic LN chain with HTT at 51.8 Gy/28 fr and with simultaneous integrated boost to a median dose of 65.5 Gy on the pathological uptake sites detected by 11C-choline-PET/CT. Nine patients were treated without simultaneous integrated boost (50-65.5 Gy, 25-30 fr). RESULTS: With a median (range) follow-up of 36 (9-116) months, 91.4% of the patients had a PSA reduction 3 months after HTT. The 3-year overall, local relapse-free and clinical relapse-free survival rates were 80.0, 89.8 and 61.8%, respectively. The 3-year actuarial incidences of ≥grade 2 rectal and ≥grade 2 genitourinary toxicity were 6.6% (±2.9%) and 26.3% (±5.5%), respectively. A PSA nadir of ≥0.26 ng/mL (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.7-7.7; P = 0.001), extrapelvic 11C-choline-PET/CT-positive LN location (HR 2.4, 95% CI 0.9-6.4; P = 0.07), RT previous to HTT (HR 2.7; 95% CI 1.07-6.9, P = 0.04) and number of positive LNs (HR 1.13, 95% CI 1.04-1.22; P = 0.003) were the main predictors of clinical relapse after HTT. CONCLUSIONS: 11C-choline-PET/CT-guided HTT is safe and effective in the treatment of LN relapses of prostate cancer in previously treated patients.
OBJECTIVE: To report the 3-year toxicity and outcomes of carbon 11 (11C)-choline-positron emission tomography (PET)/computed tomography (CT)-guided radiotherapy (RT), delivered via helical tomotherapy (HTT; Tomotherapy® Hi-Art II® Treatment System, Accuray Inc., Sunnyvale, CA, USA) after lymph node (LN) relapses in patients with prostate cancer. PATIENTS AND METHODS: From January 2005 to March 2013, 81 patients with biochemical recurrence after surgery, with or without adjuvant/salvage RT or radical RT, and with evidence of LN 11C-choline-PET/CT pathological uptake, underwent HTT (median [range] prostate-specific antigen level 2.59 [0.61-187] ng/mL). Of the 81 patients, 72 were treated at the pelvic and/or lumbar-aortic LN chain with HTT at 51.8 Gy/28 fr and with simultaneous integrated boost to a median dose of 65.5 Gy on the pathological uptake sites detected by 11C-choline-PET/CT. Nine patients were treated without simultaneous integrated boost (50-65.5 Gy, 25-30 fr). RESULTS: With a median (range) follow-up of 36 (9-116) months, 91.4% of the patients had a PSA reduction 3 months after HTT. The 3-year overall, local relapse-free and clinical relapse-free survival rates were 80.0, 89.8 and 61.8%, respectively. The 3-year actuarial incidences of ≥grade 2 rectal and ≥grade 2 genitourinary toxicity were 6.6% (±2.9%) and 26.3% (±5.5%), respectively. A PSA nadir of ≥0.26 ng/mL (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.7-7.7; P = 0.001), extrapelvic 11C-choline-PET/CT-positive LN location (HR 2.4, 95% CI 0.9-6.4; P = 0.07), RT previous to HTT (HR 2.7; 95% CI 1.07-6.9, P = 0.04) and number of positive LNs (HR 1.13, 95% CI 1.04-1.22; P = 0.003) were the main predictors of clinical relapse after HTT. CONCLUSIONS:11C-choline-PET/CT-guided HTT is safe and effective in the treatment of LN relapses of prostate cancer in previously treated patients.
Authors: William P Parker; Jaden D Evans; Bradley J Stish; Sean S Park; Kenneth Olivier; Richard Choo; Mark A Nathan; Brian T Welch; R Jeffrey Karnes; Lance A Mynderse; Thomas M Pisansky; Eugene D Kwon; Val J Lowe; Brian J Davis Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-17 Impact factor: 7.038
Authors: Ahmed Gawish; Matthias Walke; Burkard Röllich; Hans-Joachim Ochel; Thomas B Brunner Journal: J Cancer Res Clin Oncol Date: 2022-08-27 Impact factor: 4.322
Authors: Andrei Fodor; Andrea Lancia; Francesco Ceci; Maria Picchio; Morten Hoyer; Barbara Alicja Jereczek-Fossa; Piet Ost; Paolo Castellucci; Elena Incerti; Nadia Di Muzio; Gianluca Ingrosso Journal: World J Urol Date: 2018-05-11 Impact factor: 4.226
Authors: Giampiero Giovacchini; Andrea Ciarmiello; Elisabetta Giovannini; Andrei Fodor; Cesare Cozzarini; Paola Mapelli; Elena Incerti; Nadia Di Muzio; Luigi Gianolli; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-16 Impact factor: 9.236
Authors: M Oertel; S Scobioala; K Kroeger; A Baehr; L Stegger; U Haverkamp; M Schäfers; H-T Eich Journal: Radiat Oncol Date: 2018-09-21 Impact factor: 3.481
Authors: A De Bruycker; A Spiessens; P Dirix; N Koutsouvelis; I Semac; N Liefhooghe; A Gomez-Iturriaga; W Everaerts; F Otte; A Papachristofilou; M Scorsetti; M Shelan; S Siva; F Ameye; M Guckenberger; R Heikkilä; P M Putora; A Zapatero; A Conde-Moreno; F Couñago; F Vanhoutte; E Goetghebeur; D Reynders; T Zilli; P Ost Journal: BMC Cancer Date: 2020-05-12 Impact factor: 4.430
Authors: Simon Kirste; Stephanie G C Kroeze; Christoph Henkenberens; Nina-Sophie Schmidt-Hegemann; Marco M E Vogel; Jessica Becker; Constantinos Zamboglou; Irene Burger; Thorsten Derlin; Peter Bartenstein; Juri Ruf; Christian la Fougère; Matthias Eiber; Hans Christiansen; Stephanie E Combs; Arndt-Christian Müller; Claus Belka; Matthias Guckenberger; Anca-Ligia Grosu Journal: Front Oncol Date: 2021-05-10 Impact factor: 6.244